Identification of a biomarker that can inform on extracellular serotonin (5-HT) levels in the brains of living humans would enable greater understanding of the way brain circuits are modulated by serotonergic neurotransmission. Substantial evidence from studies in animals and humans indicates an inverse relationship between central 5-HT tonus and 5-HT type 4 receptor (5-HT 4 R) density, suggesting that 5-HT 4 R receptor density may be a biomarker marker for 5-HT tonus. Here, we investigated whether a 3-week administration of a selective serotonin reuptake inhibitor, expected to increase brain 5-HT levels, is associated with a decline in brain 5-HT 4 R binding. A total of 35 healthy men were studied in a placebo-controlled, randomized, double-blind study. Participants were assigned to receive 3 weeks of oral dosing with placebo or fluoxetine, 40 mg per day. Brain 5-HT 4 R binding was quantified at baseline and at follow-up with [
INTRODUCTION
Serotonin (5-HT) affects basic physiologic functions such as sleep, appetite and mood and is implicated in the pathophysiology of disorders such as depression and anxiety. Selective serotonin reuptake inhibitors (SSRIs) can ameliorate some of the symptoms presumably by elevating synaptic 5-HT and thus enhancing serotonergic neurotransmission. Currently, there is no way to assess the in vivo central extracellular 5-HT levels in humans. Finding a biomarker of the central 5-HT tonus could enable a resolution of some of the puzzling questions regarding serotonergic neurotransmission in psychiatric disorders, for example, why 40-50% of patients with major depressive disorder lack clinical response to SSRI treatment. 1 To date, a substantial number of studies have failed to provide convincing evidence for the detection of changes in brain 5-HT levels in humans. 2 Recently, two studies found increased radiotracer binding after acute challenge with SSRI. The 5-HT 1B receptor binding as determined by [ 4 The unexpected direction of change in radiotracer binding was explained by hypothesizing that the acute administration of SSRI activates the 5-HT 1A and 5-HT 1B autoreceptors in the raphe nuclei and this in turn reduces release of 5-HT in the cortical projection areas, and thereby increases the availability of postsynaptic 5-HT 1A and 5-HT 1B receptors to bind [ 11 
C]CUMI-101 or [
11 C]AZ10419369, respectively. However, an expected decrease in 5-HT 1B or 5-HT 1A receptor binding was not convincingly observed in the raphe region. 3, 4 Moreover, in a separate study, we failed to observe any changes in brain [ ) infusion. 5 Although the suitability of the available 5-HT PET radioligands to evaluate acute fluctuations in synaptic 5-HT has not been firmly established, chronic changes (weeks) in 5-HT concentration may be detectable via the effects it may have on the density of 5-HT receptors (either upregulation or downregulation of receptor density).
Ample evidence from both animal and human studies indicates that central 5-HT levels are inversely correlated with the 5-HT type 4 receptor (5-HT 4 R) density. We found that 2-and 3-week but not acute (1 day) administration of the SSRI paroxetine to the rat caused a 16-47% downregulation of 5-HT 4 R density in all brain regions examined, whereas 5-HT depletion increased 5-HT 4 R in the dorsal hippocampus, hypothalamus and lateral globus pallidus. 6 These findings were independently replicated in two studies; the 5-HT 4 R density in striatum and hippocampus decreased following a 3-week administration of the SSRI fluoxetine 7 and the serotnin noradrenaline reuptake inhibitor venlafaxine. 8 Furthermore, modified expression of the gene coding for the serotonin transporter (5-HTT) induced significant alterations in 5-HT 4 R density in mice: overexpression of the 5-HTT (that is, resulting in reduced interstitial 1 Neurobiology Research Unit, Rigshospitalet and University of Copenhagen, Copenhagen, Denmark; 5-HT levels) resulted in increased central 5-HT 4 R density, whereas knockout of the gene coding for 5-HTT (that is, resulting in increased interstitial 5-HT levels) reduced 5-HT 4 R density. 9 Studies in humans are consistent with the preclinical evidence. An acute blockade of 5-HT reuptake with citalopram does not modify the central 5-HT 4 R binding, 10 but an association between serotonin transporter-linked polymorphic region (5-HTTLPR) status and neocortical 5-HT 4 R binding provides a possibility that chronic differences in synaptic 5-HT produce changes in 5-HT 4 R density.
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The 5-HTTLPR is a genetic variant within the gene coding for the 5-HTT where the 'long' (L) allele exhibits increased 5-HTT transcription relative to the 'short' (S) allele, putatively affecting 5-HT signaling. 12 Fisher et al. 11 showed that S carriers had lower 5-HT 4 R binding relative to L homozygotes, consistent with higher 5-HT levels in the S allele because of a less effective 5-HTT, leading to a compensatory downregulation in 5-HT 4 R. Taken together, these findings suggest that the 5-HT 4 R could be used as a proxy for chronically (weeks) but not acutely (hours) altered central 5-HT levels.
We aimed to investigate whether SSRI intervention was associated with a significant decrease in central 5-HT 4 R binding. We chose the highly tolerable SSRI fluoxetine that has negligible affinity to the 5-HT 4 R as well as to muscarinic, histaminic, noradrenergic and additional serotonergic receptors. [13] [14] [15] In a randomized, double-blinded, placebo-controlled design, we used [ 11 C]SB207145 PET to measure the in vivo 5-HT 4 R binding in healthy men before and after 3 weeks of oral intervention with fluoxetine or placebo. We hypothesized that fluoxetine administration for 3 weeks would lead to a reduced central 5-HT 4 R binding, whereas placebo intervention would have no effect on central 5-HT 4 R binding.
MATERIALS AND METHODS
A total of 35 eligible healthy males were recruited through advertisements. We oversampled for 5-HTTLPR L homozygotes by genotyping participants before inclusion. Informed consent was obtained according to the declaration of Helsinki II and the study was approved by the Ethical Committee of Copenhagen. The data from the baseline PET scan of 19 participants from the present study were included as part of larger samples in previous publications. 11, 16 All participants had a normal physical and neurological examination, a normal blood screening and brain magnetic resonance (MR) imaging (MRI) results. The exclusion criteria were as follows: neurological or psychiatric disorder according to ICD-10 (International Statistical Classification of Diseases and Related Health Problems-10th revision), drug use within the past month or lifetime use of cocaine, heroin, amphetamine or ecstasy more than 10 times, lifetime use of cannabis more than 50 times and previous or current use of antipsychotics or antidepressants or other medication that significantly affect brain function. On the day of the PET scans, participants self-reported symptoms of stress and depression by means of Cohen's Perceived Stress 17 and Major Depression Index 18 and any use of illicit drugs was registered by a modified version of The Family History Assessment Module. 19 
Intervention regime
All participants received two PET scans: a baseline and a follow-up scan after receiving an intervention for 21-23 days. In order to ensure balanced groups, an unblinded researcher not involved in the data acquisition randomized the participants based on genotype, age and education to take identical capsules containing either fluoxetine (20 mg per capsule) or placebo. A blinded investigator instructed the participants to take one capsule per day for the first 3 days and hereafter two capsules per day until the follow-up PET scan was completed.
The participants and the investigators involved in the data acquisition were blinded to the intervention type until completion of data collection. Three participants were excluded before the follow-up PET scan was conducted: two because of failure of radiotracer production and one (in the placebo group) did not show up for the follow-up PET scan. Thus, 35 participants completed the baseline scan, whereas 32 completed the full study.
A blinded medical doctor contacted all participants during the intervention to ensure compliance and register side effects according to the Udvalg for Kliniske Undersøgelser (UKU) scale. 20 S-fluoxetine and the active metabolite S-norfluoxetine were assessed in the middle of the intervention period (days 12 ± 3 (mean ± s.d.)) and again on the day of the follow-up PET scan by ultra-performance liquid chromatography followed by tandem mass spectrometry. 21 
PET and MR imaging
The [ 11 C]SB207145 was synthesized using an automated radiosynthesis system as previously described. 10 Immediately after an intravenous bolus injection of [ 11 C]SB207145 was given, a 120-min dynamic threedimensional emission scan was acquired using a Siemens (Hunidu, Germany) ECAT HRRT scanner with an approximate in plane resolution of 1.5 mm. 22 The scans were reconstructed using the iterative point spread function reconstruction with attenuation map improvements. 23 MR images were acquired using a Siemens Magnetom Trio 3T MR scanner at baseline and at follow-up. A three-dimensional T1-weighted MPRAGE and a T2-weighted Turbo Spin Echo structural image were acquired and used for segmentation and brain-masking as previously described. 24 Quantification of the 5-HT 4 R binding All PET scans were corrected for intra-scan movement using AIR 5.2.5.
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The flow-weighted mean emission images from the baseline and follow-up PET scans were automatically aligned to the same individual's corresponding baseline or follow-up MRI using SPM5 (Wellcome Department of Neuroscience, Condon, UK). Accurate co-registration was confirmed by visual inspection across all planes.
The tissue concentration of radioactivity in the volumes of interest was obtained by automatic delineation of regions on each subject's MRI using the PVElab software (http://www.nru.dk/downloads). 26 The included regions (pooled left and right) were caudate, putamen, amygdala, hippocampus, entorhinal cortex, thalamus, anterior and posterior cingulate, inferior, medial, and superior frontal gyri, orbitofrontal cortex, medial inferior and superior temporal gyri, insula, occipital, parietal and sensomotor cortex.
Kinetic modeling was performed in PMOD version 3 (PMOD, Zurich, Switzerland) using the simplified reference tissue model with cerebellum as reference region. This method estimates the BP ND (binding potential (non-displaceable)) and was described and validated for quantification of [ 11 C]SB207145 binding in humans. 27 Genotyping DNA was extracted from either blood or saliva samples using Qiagen Mini Kit (Qiagen, Hilden, Germany) and prepIT kit (DNA Genotek, Kanata, ON, Canada), respectively. The 5-HTTLPR S/L polymorphism in the 5-HTT gene was determined by PCR amplification with the appropriate primers and subsequent fragment analysis by electrophoresis as previously described. 28 
Statistical data analysis
In order to evaluate global homogenous effects of increased 5-HT levels on central 5-HT 4 R levels, we constructed an occupancy plot for each participant. In these 32 plots, the baseline BP ND for each brain region was plotted on the x axis against follow-up BP ND for the same regions on the y axis. A linear relationship indicated that there was a homogeneous change and the slope of the plot, b, representing an estimate of the change in postsynaptic 5-HT 4 R density caused by the fluoxetine-induced change in synaptic 5-HT. Thus, a slope o1 indicated an overall homogeneous fractional decrease in the receptor availability because of an increase in endogenous 5-HT. We evaluated whether the mean b values for the fluoxetine and the placebo group were significantly different from 1 with a one-sample t-test and whether the mean b values obtained in each of the two groups were statistically significantly different in the two-sample t-test. Demographic data were compared with paired or unpaired t-tests.
Post hoc, we evaluated the regional binding in the included regions and compared the baseline with the follow-up BP ND with paired t-tests. Moreover, as the caudate and putamen have considerably higher 5-HT 4 R binding than other brain regions, we also constructed the occupancy plots excluding the two regions to ensure that any overall change in 5-HT 4 R density was also present without the high-binding regions.
We also attempted to reproduce our previous findings of an association between 5-HTTLPR status and the 5-HT 4 R binding. 11 The cohorts in the two studies overlapped with 19 of the 35 individuals included in this study; however, the sample in the present study was more homogeneous in terms of age (narrow range) and gender (only males). Moreover, we oversampled for L homozygosity and thus compared 13 LL with 22S carriers in the current study. We investigated with a linear regression analysis corrected for age whether 5-HTTLPR status predicted the 5-HT 4 R levels in neocortex at baseline. Contingent on any observed associations between 5-HTTLPR status and changes in central 5-HT 4 R binding after fluoxetine intervention, we tested for statistical differences between the mean b in the L homozygotes vs the S carriers.
Finally, we summed up the serum concentration of fluoxetine and its metabolite norfluoxetine, as both have equivalent potency and selectivity as serotonin uptake blockers, 29 and examined whether drug concentration on the day of the follow-up PET scan predicted the change in 5-HT 4 R binding.
A significance level of 0.05 (two tailed) was adopted in all analyses. Statistical tests were carried out using StatPlus:mac, 2008 (AnalystSoft, Alexandria, WA, USA) or Prism 6:mac, 2012 (GraphPad Software, La Jolla, CA, USA).
RESULTS
We found that 3 weeks of fluoxetine intervention was associated with a statistically significant 5.2% decrease in central 5-HT 4 R binding (mean b ¼ 0.948 (95% confidence interval (CI): 0.908-0.990), P ¼ 0.017), whereas we did not find a significant effect of placebo intervention on the 5-HT 4 R binding (mean b ¼ 0.990 (95% CI: 0.943-1.037), P ¼ 0.65; Figure 1) . A representative occupancy plot is illustrated in Figure 2 and the group effects are illustrated in Figure 3 . The baseline BP ND values were similar in the fluoxetine and the placebo group (P-values 40.32 for all regions (twosample t-test)). No statistically significant difference was found between the fluoxetine and the placebo group in mean percent change in 5-HT 4 R binding (P ¼ 0.17; Figure 1 ). In the post hoc regional analyses, we found a significant decrease in striatal 5-HT 4 R binding in the fluoxetine-treated group when comparing baseline with follow-up (baseline BP ND ¼ 3.73 ± 0.33, follow-up BP ND ¼ 3.58±0.36, P ¼ 0.039 (mean±s.d., paired t-test)) and in amygdala (baseline BP ND ¼ 0.94±0.19 and follow-up BP ND ¼ 0.85 ± 0.13, P ¼ 0.016 (mean ± s.d., paired t-test)). When the caudate and putamen were excluded from the occupancy plots, a statistically significant decrease in 5-HT 4 R binding in the remaining regions was still present (mean b ¼ 0.87 (95% CI: 0.79-0.96), P ¼ 0.007). Apart from striatum and amygdala, no single region 5-HT 4 R binding was significantly different before versus after fluoxetine (P-values 40.10 (paired t-test)).
We replicated the previous finding that the S carriers had lower 5-HT 4 R binding in neocortex than the L homozygotes 11 (reduction of 9.4%, P ¼ 0.026). Genotype did not have any statistically significant impact on the change in the 5-HT 4 R binding after fluoxetine intervention (P ¼ 0.97).
Demographic, drug-related and tracer data are shown in Table 1 . The fluoxetine and the placebo group were comparable, both at baseline and at follow-up, except that the placebo group differed on the amount of SB207145 injected in the baseline and the follow-up PET scans (P ¼ 0.036). To ensure the results of the present study did not depend on this difference, we corrected the BP ND s in both groups using the population-based occupancy dose (ID 50 ) according to Madsen et al. 30 This did not alter the results: The participants did not use illicit drugs on a regular basis: 7 participants in the fluoxetine group and 9 participants in the placebo group had tried cannabis 1-20 times; however, all use were not within the past 6 months. Two participants had taken cocaine 2-3 times years back.
When interviewed about the side effects during the intervention period, seven participants in the active group and five in the placebo group reported a few symptoms uncharacteristic for known SSRI side effects (UKU scores o5), whereas two individuals, one in each group, reported sexual dysfunction and concentration problems during the intervention (UKU score 45).
The blinding was successful; after study completion, neither the participants nor the investigators were able to correctly guess the intervention received by the study participants.
We did not find a correlation between the serum concentration of fluoxetine and norfluoxetine and the decrease in 5-HT 4 R binding (P ¼ 0.40).
DISCUSSION
We evaluated the effect of a 3-week fluoxetine intervention on 5-HT 4 R binding in healthy men using [ 11 C]SB207145 PET. Consistent with our hypothesis, we found a significant but moderate effect of fluoxetine intervention on the 5-HT 4 R binding. The individuals pharmacologically treated for 3 weeks with an SSRI-that presumably leads to increased central 5-HT levels-showed a statistically significant downregulation of their central 5-HT 4 R levels. This effect was not observed in the placebo group. The finding provides novel evidence for an effect of long-term (weeks) altered extracellular 5-HT levels on the 5-HT 4 R availability.
The finding is consistent with previous studies. The 3-week intervention with the SSRIs paroxetine or fluoxetine in rodents resulted in large reductions in the 5-HT 4 R binding (416%) in the majority of the investigated brain regions. 6, 7 On the other hand, 1-day paroxetine administration did not significantly alter 5-HT 4 R binding. 6 In humans, we previously found that acute infusion with citalopram left the [ 11 C]SB207145 binding unaltered, 10 whereas here we show that 5-HT 4 R is downregulated after 3 weeks of fluoxetine intervention. Taken together, these findings suggest that 5-HT 4 R density fluctuates following chronic (weeks), but not acute (hours), changes in central 5-HT levels. The findings are consistent with a model in which the 5-HT 4 R binding varies inversely with the 5-HT level, and we provide novel evidence that the 5-HT 4 R can be used as a biomarker for the central 5-HT tonus in humans.
The availability of an imaging biomarker for the synaptic 5-HT concentration has important clinical implications. Many affective disorders such as depression or anxiety-related disorders (for example, post-traumatic stress disorder or obsessive compulsive disorder) are possibly linked to disturbed 5-HT function and SSRI treatment ameliorates the symptoms in some but not all patients. 31, 32 However, the neurobiological mechanisms behind these heterogeneous disorders are poorly understood and a 5-HT 4 R biomarker may help elucidate the role of 5-HT in these psychiatric disorders. Questions such as whether synaptic 5-HT levels differ in patients compared with controls, and whether pharmacological treatments lead to a change in 5-HT levels, can be examined using [
11 C]SB207145 binding as a biomarker of 5-HT levels.
The observed 5.2% decrease in [ 11 C]SB207145 binding in humans was, however, modest as compared with the rodent studies where a reduction of 416% was reported. 6, 7 The effect should, however, be seen in conjunction with our finding that 5-HTTLPR S carriers had 9% lower neocortical 5-HT 4 R binding than did L monozygotes; that is, pharmacological intervention with fluoxetine in pharmacological doses induced an effect that was of similar magnitude as this genetic variant. A likely explanation of this discrepancy could be the differences in the administrated Measured at days 12 ± 3 between the two positron emission tomography (PET) scans.
Serotonin 4 receptor and a 3-week SSRI intervention ME Haahr et al fluoxetine dose. We used a fluoxetine dose of 40 mg day À 1 (B0.5 mg kg À 1 , daily) as this is an effective dose to obtain antidepressive effects in patients, and we confirmed that serum concentrations of fluoxetine were similar to clinical concentrations in depressed patients taking fluoxetine. 33 However, the doses used in the rodent studies 6, 7 were 410-fold greater and may therefore have increased the 5-HT levels more potently. Indeed, two studies applying acute SSRI challenges in two different doses in rodents found that the smaller fluvoxamine or citalopram dose corresponded to a smaller 5-HT release in the 5-HT projection areas. 34, 35 Another explanation may be that species differences in sensitivity to pharmacological intervention are known to be present for the 5-HT system anatomy, receptor distribution and innervations. 36, 37 It is possible that the 5-HT-adaptive mechanisms (5-HT 1A and 5-HT 1B autoreceptors, 5-HTT activity or monoamine oxidase A activity) may differ in humans compared with rodents. Two longitudinal studies treated mice and non-human primates with fluoxetine for 3 weeks and although the doses varied (the mice received 18 mg kg À 1 and the non-human primates received 10 mg kg À 1 ) the studies found that the 5-HT release was more pronounced in mice. 38 as compared with non-human primates. 39 These considerations taken together, we speculate whether a higher dose of fluoxetine would have provided a larger decrease in the 5-HT 4 R levels. We confirmed in a partially overlapping but smaller sample the previously observed effect of 5-HTTLPR S carriers having a lower central 5-HT 4 R than L homozygotes. 11 In contrast, we did not identify any genotype effects on the fluoxetine-associated change in 5-HT 4 R binding. This may, however, be because of insufficient statistical power as only 5L homozygotes and 11S carriers were included in the fluoxetine intervention group.
The strength of the present study was the rigorous design including randomization and blinding and homogeneity of the included healthy volunteers. Some limitations of the study should be mentioned. First, in the main analyses we assumed that SSRI intervention modulated the fractional change in 5-HT 4 R density similarly across different brain regions. This assumption may, however, not be entirely valid as it is not unlikely that in a given region, the serotonergic neurotransmission is scaled to the density of postsynaptic receptors. Second, we employed a quantification method that requires use of a reference region for estimation of the nondisplaceable binding. In order to ensure that fluoxetine intervention did not induce alterations in nondisplaceable binding, we used the area under the cerebellar time-activity as a proxy measure of the amount of ligand in cerebellum to assess this aspect. We found no difference between the fluoxetine and the placebo intervention in terms of nondisplaceable binding (P ¼ 0.41, Table 1 ).
In conclusion, we provide novel evidence that the central 5-HT 4 R binding in humans constitutes a biomarker for the extracellular 5-HT tonus. Our findings corroborate previous animal studies showing a monotonic regulation of the 5-HT 4 R relative to 5-HT tonus. Therefore, imaging of the central 5-HT 4 R binding may provide a noninvasive measure of synaptic 5-HT levels in the 5-HT projection areas. Access to such a measure could provide clinical information about the pathophysiology of, for example, mood disorders and have implications for treatment strategies and, moreover, provide an important tool in longitudinal intervention studies to monitor the dynamics of serotonergic signaling.
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